←
Sinead Stoneman7,216 posts
Sinead Stoneman avatar

Sinead Stoneman

@Stones__

Irish Nephrology SpR.

◷ Joined March 2013▧ 514 Photos and videos
Nephrology Journal Club avatar
⟳ Sinead Stoneman retweeted
Nephrology Journal Club@NephJC·11 Nov 2024

10/10 Final #nephjc thoughts ✳️ The 🔑 takeaway from this study is straightforward 👉 initiate #SGLT2i early, ensure consistent therapy, & recognize that the protective effects are not sustained after discontinuation. Flozinate early and persist with flozination.

Post attachment
Tiffany Caza avatar
⟳ Sinead Stoneman retweeted
Tiffany Caza@Tiff_Caza·10 Nov 2024

Monotypic fibrillary glomerulonephritis is not a MGRS in the vast majority of cases. In cases with monotypic fibrillary - do IgG subclasses, do par IF, and check SPEP/UPEP for evaluation of true clonality. Insights from @VBijol and @MayoClinicPath at @GlomCon

Post attachmentPost attachment
Andrew—#IAmTheResistance avatar
⟳ Sinead Stoneman retweeted
Andrew—#IAmTheResistance@AmoneyResists·9 Nov 2024

Holy shit this is INCREDIBLE work from @ByDonkeys. And bonus points for projecting the entire thing on @Tesla headquarters, effectively turning @elonmusk’s building’s most visible exterior side into a cinema screen to broadcast the tale of his corruption and political malfeasance

9:45
Hans-Joachim Anders avatar
⟳ Sinead Stoneman retweeted
Hans-Joachim Anders@hjanders_hans·7 Nov 2024

Now open access in @NDTsocial @fervenzafernan1 @fcaravacafontan Hydroxychloroquine for all patients with lupus nephritis: No! 🧐"In an era of modern immunosuppression ... HCQ for all no longer makes sense" "Yes" part will come in @NDTsocial soon ▶️academic.oup.com/ndt/article…

Sinead Stoneman avatar
Sinead Stoneman@Stones__·7 Nov 2024

Interesting viewpoint from @jingelfinger Way Stations in Progress — Burgeoning Treatment Options for IgA Nephropathy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Will Herrington avatar
⟳ Sinead Stoneman retweeted
Will Herrington@willkidney·6 Nov 2024

#NephJC proteinuria is a surrogate of a surrogate (eg. eGFR decline) which is itself a surrogate of clinical kidney failure…& there is no surrogate for safety. Our community must prioritise large trials wherever we can…our patients deserve better!